nordazepam and fluvoxamine

nordazepam has been researched along with fluvoxamine in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (33.33)	18.2507
2000's	2 (66.67)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Topliss, JG; Yoshida, F	1
Adkison, KK; Humphreys, JE; Mahar Doan, KM; Polli, JW; Serabjit-Singh, CJ; Shampine, LJ; Webster, LO; Wring, SA	1
Barel, S; Bialer, M; Cipolla, G; Gatti, G; Gips, M; Perucca, E; Soback, S; Spina, E	1

Trials

1 trial(s) available for nordazepam and fluvoxamine

Article	Year
Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clinical pharmacology and therapeutics, 1994, Volume: 56, Issue:5 Topics: Adult; Biotransformation; Diazepam; Female; Fluvoxamine; Humans; Male; Nordazepam	1994

Other Studies

2 other study(ies) available for nordazepam and fluvoxamine

Article	Year
QSAR model for drug human oral bioavailability. Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13 Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship	2000
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. The Journal of pharmacology and experimental therapeutics, 2002, Volume: 303, Issue:3 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Cell Line; Cell Membrane Permeability; Central Nervous System Agents; Dogs; Drug Delivery Systems; Permeability; Pharmaceutical Preparations	2002

Article

Year

QSAR model for drug human oral bioavailability.

Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13

Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship

2000

Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.

The Journal of pharmacology and experimental therapeutics, 2002, Volume: 303, Issue:3

Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Cell Line; Cell Membrane Permeability; Central Nervous System Agents; Dogs; Drug Delivery Systems; Permeability; Pharmaceutical Preparations

2002